Life Science

Pharma's Almanac: In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?

This article was originally published in July 2023 on Pharma's Almanac. Here is an excerpt:

Cristina Varner, Senior Vice President and National Life Science and Digital Health & Telemedicine Practice Leader, Newfront

"The potential applications of machine learning in pharma/biopharma are vast, and the technology is likely to transform the industry in the years to come.  Like many industries, the life sciences industry overall needs to continue to evolve and improve efficiencies. Machine learning can help optimize clinical trials by identifying patient populations that are most likely to respond to a particular therapy. AI algorithms can help identify and screen patients who are suitable for clinical trials by analyzing large data sets and electronic health records. The algorithms can match patients with specific eligibility criteria and engage them through online platforms, leading to faster enrollment and recruitment.  These applications could potentially be useful in streamlining the variability and complexity of clinical trial insurance. AI can monitor patients remotely, eliminating time-consuming and costly regular hospital or site visits.  AI has the potential to improve the efficiency, accuracy, and safety of clinical trials by optimizing various processes from recruitment to patient monitoring and data analysis."

The information provided is of a general nature and an educational resource. It is not intended to provide advice or address the situation of any particular individual or entity. Any recipient shall be responsible for the use to which it puts this document. Newfront shall have no liability for the information provided. While care has been taken to produce this document, Newfront does not warrant, represent or guarantee the completeness, accuracy, adequacy, or fitness with respect to the information contained in this document. The information provided does not reflect new circumstances, or additional regulatory and legal changes. The issues addressed may have legal, financial, and health implications, and we recommend you speak to your legal, financial, and health advisors before acting on any of the information provided.